Overview

This trial is active, not recruiting.

Condition leukemia
Treatments gene expression analysis, mutation analysis, polymorphism analysis, protein analysis, flow cytometry, laboratory biomarker analysis
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date July 2008
End date August 2099
Trial size 40 participants
Trial identifier NCT00897559, CDR0000600323, ECOG-E1900T3

Summary

RATIONALE: Studying the genes expressed in samples of bone marrow from patients with cancer may help doctors identify biomarkers related to cancer.

PURPOSE: This research study is looking at bone marrow samples from patients with acute leukemia.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Measure
Correlation of gene mutations with adult acute megakaryoblastic leukemia (AMKL)
time frame:
Ability of Src kinase inhibitors (SU6656, dasatinib) to induce differentiation of AMKL blasts
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diagnosis of adult acute megakaryoblastic leukemia - Archived bone marrow specimens from the ECOG tissue repository PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Identifying the Genetic Basis of Adult AMKL
Description OBJECTIVES: - To perform high throughput sequencing of a set of megakaryocyte specific transcription factors, tyrosine kinases, and Src kinases in DNA isolated from bone marrow specimens of adults with acute megakaryoblastic leukemia (AMKL). - To assay the ability of Src kinase inhibitors (SU6656, dasatinib) to induce differentiation of AMKL blasts in these patients. OUTLINE: DNA from previously collected bone marrow samples are sequenced to analyze genes associated with transcription factors (GATA1, GATA2, SCL, FOG-1, ETS1, ETS2, ERG, FLI-1, GABP, HOXA11, NF-E2, and RUNX1), tyrosine kinases (JAK2, JAK3, and c-MPL), and Src family kinases (LYN, FYN, and HCK) and compared with control DNA. Using bioinformatics, gene alterations are compared to known polymorphisms and subsequent changes in the amino acid sequence of the encoded protein. Subsequent assays assess the effect on proliferation and differentiation and in vitro studies evaluate the consequences of mutations on transcription factor and kinase activity abilities. The effect of SU6656 and dasatinib on cell death and polyploidization is evaluated by flow cytometry and compared with control DNA.
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by Eastern Cooperative Oncology Group.